Table 1.
Novel therapeutics currently under development (clinical trials), for the treatment of influenza virus, respiratory syncytial virus (RSV), and Middle East respiratory syndrome coronavirus (MERS-CoV).
| Therapeutic compound | Infectious agent | Mechanism(s) of action | Clinical trial phase | NCT# |
|---|---|---|---|---|
| CR6261 | Influenza | Inhibits the binding of the virus to cell membrane receptor | 2a | NCT02371668 |
| CT-P27 | Influenza | Inhibits the binding of the virus to cell membrane receptor | 2b |
NCT03511066 NCT02071914 |
| MEDI8852 | Influenza | Inhibits the binding of the virus to cell membrane receptor | 2a |
NCT03903718 NCT03028909 NCT02603952 |
| MHAA4549A | Influenza | Inhibits the binding of the virus to cell membrane receptor | 2 |
NCT01980966 NCT02623322 NCT02293863 |
| Pimodivir | Influenza | Prevents viral RNA synthesis | 3 | NCT03381196 |
| Favipiravir | Influenza | Inhibits the activity of the RNA-dependent RNA polymerase | 3 |
NCT02026349 NCT02008344 |
| Fludase | Influenza | Prevents viral entry into cells of the respiratory epithelium | 2 | NCT01037205 |
| Nitazoxanide | Influenza | Impairs the trafficking of the viral hemagglutinin | 3 | NCT03336619 |
| RI-001 | RSV | Inhibits the binding of the virus to cell membrane receptor | 2 | NCT00632463 |
| REGN2222 | RSV | Viral fusion protein inhibitor | 3 | NCT02325791 |
| MEDI8897 | RSV | Viral fusion protein inhibitor | 2 | NCT02878330 |
| ALX-0171 | RSV | Viral fusion protein inhibitor | 2 | NCT03418571 |
| 131-2G | RSV | Interferes with the attachment process by blocking the G protein | Pre-clinical | NA |
| Motavizumab | RSV | Viral fusion protein inhibitor | 3 |
NCT00121108 NCT00628303 NCT00129766 |
| GS-5806 | RSV | Blocks the virus-cell fusion process | 2 |
NCT01756482 NCT02534350 NCT02254408 NCT02254421 NCT02135614 |
| MDT-637 | RSV | Inhibits virus entry to the target cells | 1 |
NCT01489306 NCT01355016 NCT01556607 |
| JNJ-53718678 | RSV | Viral fusion protein inhibitor | 2 |
NCT03656510 NCT03379675 NCT02387606 |
| AK-0529 | RSV | Inhibits virus entry to the target cells | 2 |
NCT03699202 NCT02654171 |
| TMC353121 | RSV | Viral fusion protein inhibitor | Pre-clinical | NA |
| RSV-60444 | RSV | Inhibits RNA synthesis and the infectivity of released viruses | 2a | NCT00232635 |
| ALN-RSV01 | RSV | Inhibits RNA replication | 2 |
NCT00658086 NCT01065935 NCT00496821 |
| ALS-008176 | RSV | Inhibits RSV polymerase | 2 |
NCT02094365 NCT02673476 |
| Convalescent plasma | MERS-CoV | Inhibits virus entry to the target cells | 2 | NCT02190799 |
| SAB-301 | MERS-CoV | Inhibits virus entry to the target cells | 1 | NCT02788188 |
| REGN 3051 and REGN 3048 | MERS-CoV | Inhibits virus entry to the target cells | 1 | NCT03301090 |
| Ribavirin | MERS-CoV | Interferes with the synthesis of viral mRNA | 1 | NCT02627378 |